← back to search

Surinder Kaur

University of Bristol · GB
Area of research
Oncology · Radiology, Nuclear Medicine and Imaging
Research interest
Research interests include Monoclonal and Polyclonal Antibodies Research, HER2/EGFR in Cancer Research, Cytokine Signaling Pathways and Interactions, and Biosimilars and Bioanalytical Methods.
h-index
45
citations
7,731
works
166
NIH funding
—
primary concept
—
email
✉ Find email ↗

Recent publications

Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies
Clinical Cancer Research 2014cited by 65position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Priti S. Hegde · Foundation Medicine (United States)1 papers (2014–2014)John Bothos · Vividion Therapeutics (United States)1 papers (2014–2014)Ravi Salgia · City Of Hope National Medical Center1 papers (2014–2014)Rebecca A. Moss · University College London1 papers (2014–2014)Premal H. Patel · Parul University1 papers (2014–2014)Steve Eppler · University of Chicago1 papers (2014–2014)Amy Peterson · Colorado State University1 papers (2014–2014)Ihsan Nijem · Gene Therapy Laboratory1 papers (2014–2014)Janice M. Mehnert · Eastern Cooperative Oncology Group1 papers (2014–2014)Blasé N. Polite · University of Chicago Medical Center1 papers (2014–2014)Mark J. Ratain · University of Chicago1 papers (2014–2014)Shuang Bai · Peking University1 papers (2014–2014)Daniel V.T. Catenacci · University of Chicago1 papers (2014–2014)Wei Yu · Sir Run Run Shaw Hospital1 papers (2014–2014)